BRAF and skin basal cell carcinoma: Indeed while identification of mutations in BRAF for advanced melanoma and Hedgehog signalling for BCC has paved the road to clinical use of BRAF and smoothened inhibitors respectively, a similar direct translation has not occurred in cSCC [39].